Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis

The aim of the study is to evaluate the level of neutralizing antibody against SARS-CoV-2 after COVID-19 vaccination in patients under hemodialysis. To this end, the level of neutralizing antibody of patients under hemodialysis is compared to that of healthy population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Chronic Disease Coronaviridae Infections Coronavirus Infections Disease Attributes End-stage Renal Disease Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hemolysis Infections Kidney Diseases Kidney Failure, Chronic Lung Diseases Male Urogenital Diseases Nidovirales Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral RNA Virus Infections Renal Insufficiency Renal Insufficiency, Chronic Respiratory Tract Diseases Respiratory Tract Infections Urogenital Diseases Urologic Diseases Vaccine Reaction Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hanyang University Seoul Hospital

Seoul, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The person who is vaccinated with ChAdOx1 (COVID-19 vaccine)
The person who agrees with the protocol of the study

Exclusion criteria

Age < 18 years
Pregnants
Experience of COVID-19 infection

Treatment and study plan

Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)

Diagnostic Test

The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.

Primary outcomes

The change in the level of neutralizing antibody against SARS-CoV-2

Time frame: Day 0, 14, 28, 56, 91, 120

Sponsors and collaborators

Lead sponsor

Hanyang University Seoul Hospital

Other

Collaborators

Seegene Medical Foundation

Registry information

Official study title

Evaluation of Protective Antibody Production After COVID-19 Vaccination Among Patients Under Hemodialysis

Important dates

Study start: 2021
Primary completion: 2021
Study completion: 2021
First posted: May 4, 2021
Registry last updated: Mar 17, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed